Navigation Links
Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk

FDA Recommends Clinicians Temporarily Suspend Use of Vaccine as Agency Learns More

SILVER SPRING, Md., March 22 /PRNewswire-USNewswire/ -- FDA is recommending that healthcare practitioners temporarily suspend use of the Rotarix vaccine for rotavirus immunization in the United States while the agency learns more about components of an extraneous virus detected in the vaccine.  There is no evidence at this time that this finding poses a safety risk.


The agency recently became aware that an independent U.S. academic research team, using a novel technique, has found DNA from porcine circovirus 1 (PCV1) in Rotarix, which is manufactured by GlaxoSmithKline.  PCV1 is not known to cause illness in humans or other animals.  In addition, Rotarix has been studied extensively, before and after approval, and found to have an excellent safety record.

Follow-up tests by GlaxoSmithKline and FDA scientists confirmed the academic team's findings and confirmed that viral components have been present since the early stages of the vaccine's development, including during clinical studies.  Preliminary testing by both the academic researchers and FDA scientists of another licensed vaccine against rotavirus infection, RotaTeq, has not detected components of PCV1.

"We are making clinicians aware of information recently received by FDA about the Rotarix vaccine," said Dr. Margaret A. Hamburg, Commissioner for Food and Drugs. "There is no evidence at this time that there is a safety concern.  FDA is recommending that clinicians temporarily suspend use of Rotarix until we can learn more about the situation.  We will keep the public and the clinical community updated on our findings."

Rotarix and RotaTeq are given by mouth to young infants to prevent rotavirus disease, which can cause severe diarrhea and dehydration and is estimated to be responsible for the deaths of more than 500,000 infants around the world each year, primarily in low- and middle-income countries.  Before the introduction of a rotavirus vaccine, rotavirus resulted in more than 50,000 hospitalizations and several dozen deaths in the United States each year.  FDA licensed RotaTeq in 2006 and Rotarix in 2008.  Most children vaccinated in the United States received RotaTeq.

"In many countries, rotavirus causes so much severe illness and death that the known benefits of continued use of Rotarix far outweigh any theoretical risk of harm from the vaccine," said Dr. Thomas Frieden, Director of the Centers for Disease Control and Prevention.  "We anticipate that many countries will decide to continue vaccinating with Rotarix while more information becomes known."

FDA will continue to gather more information about the PCV1 components in Rotarix, including whether intact virus, as opposed to DNA fragments, is present.  The agency is assessing current vaccine testing methods.  In four to six weeks, FDA will convene an expert advisory committee and make additional recommendations on the use of rotavirus vaccines.

FDA will provide updates to patients, providers, and the general public as more information becomes available.  The agency will also continue to communicate with the World Health Organization and counterpart regulatory agencies in other countries.

For more information;

Media Inquiries: Shelly Burgess, 301-796-4651;

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Back to top



SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HHS Activates Additional Components of National Disaster Medical System to Help U.S. Hospitals Treat Survivors of Earthquake in Haiti
2. Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System
3. Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
4. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
5. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
9. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
10. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
11. Researchers Train the Immune System to Deliver Virus That Destroys Cancer in Lab Models
Post Your Comments:
(Date:10/13/2015)...  The Alliance for Safe Biologic Medicines ... 401 U.S. pharmacists showing strong support for distinguishable names ... transparency in labeling. Michael Reilly . ... survey reinforces what ASBM has been hearing from pharmacists ... that they prefer distinguishable names and more complete specific ...
(Date:10/13/2015)... October 13, 2015 TriGuard™ Cerebral ... additional findings from the multicenter Neuro-TAVR study with the ... San Francisco this week. ... it will be sharing additional findings from the multicenter ... Therapeutics (TCT) meeting in San Francisco ...
(Date:10/13/2015)... BROOMFIELD, Colo. , Oct. 13, 2015  The ... a global leader in musculoskeletal healthcare, will showcase its ... North American Spine Society (NASS) annual meeting, October 14-17, ... Biomet will also host two clinical events: ... Hall Floor Presentation Wednesday, October 14 12:30 – 1 ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... Sir Grout of ... to the local Boston chapter of Ronald McDonald House Charities® (RMHC®). This donation was ... supported Sir Grout of Greater Boston since its inception. , “We believe strongly in ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... of anesthesia and pain management services, today announced its partnership with WPC ... integrates data from disparate systems and organizes the data into an aggregated data ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to ... Summit and NAVUG Summit are independent user conferences designed and led by users ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology company ... a significant contract that will provide its award-winning private messaging solution to Independence ... growing success of its Relay program, IBX Wire™, which now has over 550,000 ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy ... SmileCareClub , the leading remote invisible aligner system, has joined with Global Dental ... without it. For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit ...
Breaking Medicine News(10 mins):